Home › Funds › Grantham, Mayo, Van Otterloo & Co. LLC › GSK
Grantham, Mayo, Van Otterloo & Co. LLC position in GSK
GSK PLC · Health Care
Grantham, Mayo, Van Otterloo & Co. LLC reported holding 3,917,951 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$188.7M, representing 0.41% of its reported portfolio and ranking #40 among its reported holdings. Grantham, Mayo, Van Otterloo & Co. LLC has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Grantham, Mayo, Van Otterloo & Co. LLC's GSK position evolved
Grantham, Mayo, Van Otterloo & Co. LLC first disclosed a stake in GSK in Q3 2023 at 1,266,444 shares (US$45.9M). The position peaked in Q1 2026 at 3,522,566 shares, worth US$194.4M. Across 13 filings, Grantham, Mayo, Van Otterloo & Co. LLC increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,917,951 shares valued at US$188.7M — an increase of 318,430 shares quarter over quarter.. Notable position changes include a 108% increase in Q2 2024 (shares rose 6% over the following quarter), a 48% trim in Q1 2025 (shares were roughly flat over the following quarter), a 36% increase in Q4 2025 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.27M | $45.91M | New |
| Q4 2023 | 1.68M | $62.22M | Add |
| Q1 2024 | 1.51M | $64.69M | Reduce |
| Q2 2024 | 3.15M | $121.10M | Add |
| Q3 2024 | 3.71M | $151.54M | Add |
| Q4 2024 | 4.15M | $140.48M | Add |
| Q1 2025 | 2.14M | $82.93M | Reduce |
| Q2 2025 | 2.60M | $99.90M | Add |
| Q3 2025 | 2.57M | $111.01M | Reduce |
| Q4 2025 | 3.49M | $171.12M | Add |
| Q1 2026 | 3.52M | $194.41M | Add |
| Q2 2026 | 3.60M | $188.69M | Add |
| Q3 2026 | 3.92M | $188.73M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.19M sh · $1.21B · Q3 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- EQUITY INVESTMENT CORP 3.56M sh · $171.52M · Q3 2026
More on Grantham, Mayo, Van Otterloo & Co. LLC
FAQ
How long has Grantham, Mayo, Van Otterloo & Co. LLC held GSK?
Grantham, Mayo, Van Otterloo & Co. LLC has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Grantham, Mayo, Van Otterloo & Co. LLC's current position in GSK?
As of Q3 2026, Grantham, Mayo, Van Otterloo & Co. LLC holds 3.92M shares of GSK (GSK PLC), valued at $188.73M, representing 0.41% of its reported portfolio and ranking #40.
Has Grantham, Mayo, Van Otterloo & Co. LLC been buying or selling GSK?
In the latest 13F filing (Q3 2026), Grantham, Mayo, Van Otterloo & Co. LLC increased its position in GSK. The position peaked in Q1 2026 at 3.52M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.